Necitumumab
- Generic Name
- Necitumumab
- Brand Names
- Portrazza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 906805-06-9
- Unique Ingredient Identifier
- 2BT4C47RUI
- Background
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant p...
- Indication
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath